

KCMC Clinical Trials Unit	STANDARD OPERATING PROCEDURE	Effective Date	SOP-Number CTU 003-02
		Page 1 of 13	09 OCT 2006
Title: ESSENTIAL DOCUMENTS			
SOP References:		Supersedes: N/A	
 Author/Date: Julieta Giner, RN			
 Approvals/Date: <div><div>John Crump, MB, ChB, DTM&H KCMC-Duke Collaboration Site Manager</div><div>John A. Bartlett, MD KCMC-Duke Collaboration, Site Principal Investigator</div></div>			
Annual Review:	Review Date	Revision Date	Signature
 Document History:			
Version Number	Reason for Changes	Date	
N/A	Initial	10 MAY 2005	
CTU 00	Standardize format	09 OCT 2006	
 Page 1 of 9			

KCMC Clinical Trials Unit	STANDARD OPERATING PROCEDURE	Effective Date	SOP-Number CTU 003-02
		Page 2 of 13	09 OCT 2006
Title: ESSENTIAL DOCUMENTS			
SOP References:		Supersedes: N/A	

Distributed to:	Name/Location	# of Copies	Name/Location	# of Copies

Purpose

This SOP is adapted from the ACTG Essential Document SOP for the KCMC CTU. The purpose of this SOP is to describe what constitutes essential documents that make up the site regulatory file, and guidance in their filing throughout the course of a study.

Essential documents are those documents that individually and collectively permit evaluation of both the conduct of a clinical trial and the quality of the data that are produced. These documents are generated throughout the various stages of a clinical trial, including, before the trial begins, during the conduct of the trial, and after completion or termination of the trial. Essential documents serve to demonstrate the compliance of the investigator, sponsor, and monitor with the standards of good clinical practice (GCP) and with all applicable regulatory requirements. These documents are also the ones that are usually audited by the sponsor and regulatory authorities as part of the process to confirm the validity of the trial conduct and integrity of the data.

Scope

This SOP is based upon: 1) the Code of Federal Regulations (CFR), 2) guidances that apply to the involvement of human subjects in clinical research, and 3) standards for GCP. This SOP is applicable to all AIDS clinical research trials, including therapeutic, vaccine, or prevention studies on human subjects, both domestic and internationally occurring at this site.

KCMC Clinical Trials Unit	STANDARD OPERATING PROCEDURE	Effective Date	SOP-Number CTU 003-02
		Page 3 of 13	09 OCT 2006
Title: ESSENTIAL DOCUMENTS			
SOP References:		Supersedes: N/A	
Instructions			
<ul style="list-style-type: none">• In addition to the list of essential documents in this SOP are, 1) a description of the purpose and/or requirements of each document, 2) a recommendation whether the document should be filed in a central file, protocol files, or subject records• It is acceptable to combine some of the documents, as long as the individual elements are readily identifiable. All documents do not have to be combined in one regulatory file. It is suggested that a memorandum be placed in the central binder to identify location of these documents.• Regulatory files must be maintained for all trial sites. It is acceptable for a main site/center/unit to maintain regulatory files for their affiliated sites/subunits if necessary.• A trial site is the location where the research is conducted and the term site is generally used in this document in place of the terms: unit, main unit, subunit, affiliated site, or center.• All of the documents addressed in this SOP must be available for audit/inspection by the sponsor and regulatory authorities.• Documents may be saved in an electronic format when appropriate. It is suggested that a memorandum be placed in the central binder to identify location of these documents.• Always refer to local, institution, and/or institutional review board (IRB)/independent ethics committee (IEC) policies/regulations and aim to follow any procedures that are more stringent than KCMC SOPs.• Of important note: Informed consents and regulatory documents are not to be included in the SOP for destroying case report forms (CRFs). Destruction or retention of these documents should be in accordance with local regulatory authority, sponsor regulations, and institution, IRB/IEC policies and procedures. Prior to destroying any research files always contact the sponsor.• Resource tools (e.g., Lab Processing Charts) are not included as essential documents.			

Page 3 of 9

KCMC Clinical Trials Unit	STANDARD OPERATING PROCEDURE	Effective Date	SOP-Number CTU 003-02
		Page 4 of 13	09 OCT 2006
Title: ESSENTIAL DOCUMENTS			
SOP References:		Supersedes: N/A	

Document	Requirement / Purpose	File	Reference
Assent Form	<p>Assent of children and permission of parents or legal guardians as determined by the IRB/IEC is required as per the provisions of 45CFR46.</p> <ul style="list-style-type: none"> State law where the research is taking place defines the age of a minor and requirements for emancipation. Local IRB/IEC determine the age for obtaining assent. The requirement for assent of children and/or permission of their parents or legal guardians may be waived by the IRB/IEC as long as the criteria for waiving consent in the regulations (45CFR46) are met. Keep on file all versions submitted and approved by site's IRB/IEC. 	<ul style="list-style-type: none"> Central file Protocol file Subject's research record 	<ul style="list-style-type: none"> 45CFR46, Subpart D 21CFR50 21CFR56 FDA Information Sheets, Guidance for IRBs and Investigators 1998 Update, FAQ Nos. 47 and 48; and Page 5
Assurance Number	<p>The Institution is responsible for obtaining and maintaining a current Project Assurance through the Office for Human Research Protections (OHRP).</p> <ul style="list-style-type: none"> The principal investigator (PI) is responsible for ensuring that a current Assurance is in effect while conducting research on human subjects in HHS funded studies. All performance sites: <ul style="list-style-type: none"> ➤ Main site ➤ All affiliated sites that meet the OHRP requirements for having an Assurance. Must be renewed prior to expiration. Keep on file the Assurance number and expiration date. 	<ul style="list-style-type: none"> Central file <p>Note: A copy of the actual Assurance document must be on file with the Institution and/or IRB/IEC.</p>	<ul style="list-style-type: none"> 45CFR46 OHRP Procedures for Registering IRBs and Filing Federal-wide Assurances of Protection for Human Subjects (FWA)

Case Report Forms	<ol style="list-style-type: none"> Dated, completed case report forms (CRFs): <ul style="list-style-type: none"> To document that the investigator or authorized member of the investigator's staff confirms the observations recorded. To document all changes/ additions or corrections made to CRF after initial data were recorded. Signed if required by Group SOPs. Originals retained by sponsor after study completion and/or site closure. Site retains copy. Refer to the KCMC Source Documentation SOP for CRFs used as source documentation. 	<ul style="list-style-type: none"> Protocol file Subject's research record Data file 	<ul style="list-style-type: none"> 21CFR312 FDA Guidance: E6 Good Clinical Practice (GCP), Sections 1.11, 4.9, 5.5, 5.23, 8.3.14, 8.3.15 KCMC SOP: Storage of CRFs and Pharmacy Records KCMC CRF Destruction List KCMC SOP: Source Documentation
Communications	<ol style="list-style-type: none"> All relevant communications, other than site visits, to document any agreements or significant discussions 	<ul style="list-style-type: none"> Protocol file 	<ul style="list-style-type: none"> FDA Guidance: E6 GCP, Sections 4.4,

KCMC Clinical Trials Unit		STANDARD OPERATING PROCEDURE	Effective Date	SOP-Number CTU 003-02
			Page 5 of 13	09 OCT 2006
Title: ESSENTIAL DOCUMENTS				
SOP References:			Supersedes: N/A	
	regarding trial administration, protocol violations, trial conduct, adverse event (AE) reporting, etc. For example: <ul style="list-style-type: none"> • Letters • Meeting notes • Notes of telephone calls • Email messages 2. Includes communications to and from the Sponsor and/or the protocol team. 3. Communications about a specific subject must be filed with source documents in the subject's research record. 4. Save electronic media, originals, and/or certified copies.			4.9, 8.3.11
Curriculum Vitae (CV)	1. The site must have on file CVs and/or other relevant documents evidencing qualifications and eligibility to conduct the trial and/or provide medical supervision of subjects. Includes the following key personnel: <ul style="list-style-type: none"> • Principal investigator (i.e., individual responsible for the grant/contract at the site). • Investigator responsible for day-to-day activities of the site. • For Investigational New Drug (IND) studies: <ul style="list-style-type: none"> ➤ Investigator of Record (IOR) ➤ All other investigators/subinvestigators and any other clinicians listed on a Form FDA 1572, Box # 6. • For non-IND studies, all other investigators/subinvestigators and any other clinicians listed on an authorized prescribers list. • Study coordinator • Pharmacist of record 2. Update to reflect significant changes: <ul style="list-style-type: none"> • Affiliation • Education • Responsibilities 3. Refer to the Protocol Registration Policy and Procedure Manual for additional requirements (e.g., CV content).	<ul style="list-style-type: none"> • Central file • Protocol file 		<ul style="list-style-type: none"> • 21CFR312 • FDA Guidance: E6 GCP, Sections 4.1, 4.3, 5.6, 8.2.10, 8.3.5 • Protocol Registration Policy and Procedure Manual
<div>Page 5 of 9</div>				

KCM Final Clinical Trials Close Out Monitoring Report Unit ESSENTIAL DOCUMENTS SOP References:	STANDARD OPERATING PROCEDURE 1. A close-out report by the monitor to document that all activities required for site close-out are completed and essential documents are in the appropriate files. Includes the following: <ul style="list-style-type: none"> • Disposition of subjects • Location of research records • Disposition of specimens • Disposition of study drug • IRB/IEC notification 	Effective Date <ul style="list-style-type: none"> • Central file Page 6 of 13	SOP-Number CTU 003-02 <ul style="list-style-type: none"> • FDA Guidance: E6 GCP, Sections 4.13, 8.4.5 09 OCT 2006 Supersedes: N/A
Final Study Report	2. Applies only to sites being closed (i.e., no longer enrolling new subjects or following any subjects on-study). Final report by the investigator to the IRB/IEC, and where applicable, to the regulatory authorities to document completion of the trial. Include the following information: <ul style="list-style-type: none"> • Disposition of subjects • Location of research records • Disposition of specimens • Disposition of study drug • Other information as required by the institution or local IRB/IEC (e.g., number of patients screened, number enrolled, serious adverse experiences, etc.). 	<ul style="list-style-type: none"> • Central file • Protocol file 	<ul style="list-style-type: none"> • 21CFR312 • FDA Guidance: E6 GCP, Sections 4.13, 8.4.7
Financial Disclosure	1. To document financial aspects of the trial and the financial agreement between the investigator / institution and the sponsor for the trial. 2. Certification or Disclosure <ul style="list-style-type: none"> • Certify that there is no financial interest, or • Disclose specific financial interests. • Must complete Forms FDA 3454 or 3455, or equivalent forms. 3. Applies to investigators and subinvestigators 4. Applies to individuals who fit any of the following criteria: <ul style="list-style-type: none"> • Sign the Form FDA 1572 (Investigator of Record) • Identified as an investigator in initial submissions or protocol amendments under an IND. • Identified as an investigator in the New Drug Application (NDA). • For studies not conducted under an IND, the individuals whom the sponsor considers to be investigators and subinvestigators. • Individuals who actually conduct and take responsibility for an investigation. • Individuals who have the ability and opportunity to significantly impact the data <i>as determined by the site</i>. • Spouses and dependent children of individuals indicated above. 5. Local institution, IRB/IEC and/or Group SOPs may have additional requirements.	<ul style="list-style-type: none"> • Central file • Protocol file 	<ul style="list-style-type: none"> • 21CFR54 • 42CFR50, Subpart F • 21CFR312 • FDA Guidance: E6 GCP, Section 8.2.4 <ul style="list-style-type: none"> • FDA Guidance: Financial Disclosure by Clinical Investigators <ul style="list-style-type: none"> • NIH Notice OD-00-040

KCMC Clinical Trials Unit		STANDARD OPERATING PROCEDURE	Effective Date	SOP-Number CTU 003-02
			Page 7 of 13	09 OCT 2006
Title: ESSENTIAL DOCUMENTS				
SOP References:			Supersedes: N/A	
Form FDA 1572	<ol style="list-style-type: none"> 1. Required for each initial protocol registration submission of a new protocol with an IND. 2. The Investigator listed in box 1 of the 1572 is the individual who must sign and date the form. This individual is referred to as the Investigator of Record (IOR). 3. Only laboratories not specified in the protocol need to be listed in Section 4. 4. Section 6 must list any individual: <ul style="list-style-type: none"> • Responsible for the medical management of subjects. • Authorized to prescribe study medication. • This may include, but is not limited to, the following: <ul style="list-style-type: none"> ➢MDs ➢Pharmacists ➢Nurse Practitioner ➢Physician's Assistant ➢Study Coordinator • If there are no individuals that need to be listed, then record "NONE". 5. Update as study personnel and/or other data on the form changes. Updated forms must be signed and dated by the IOR. 6. A copy of the forms must be kept on file at the site. 		<ul style="list-style-type: none"> • Central file • Protocol file 	<ul style="list-style-type: none"> • 21CFR312 • FDA Guidance: E6 GCP, Sections 4.1, 4.3 • Protocol Registration Policy and Procedure Manual
	Information Given to Trial Subject		<ul style="list-style-type: none"> • Central file • Protocol file 	<ul style="list-style-type: none"> • 45CFR46 • 21CFR50 • 21CFR56 • FDA Guidance: E6 GCP, Sections 4.8, 8.2.3

KCMC Clinical Trials Unit	STANDARD OPERATING PROCEDURE	Effective Date	SOP-Number CTU 003-02
		Page 8 of 13	09 OCT 2006
Title: ESSENTIAL DOCUMENTS			
SOP References:		Supersedes: N/A	
	<ol style="list-style-type: none">Written informed consent form to document that consent is:<ul style="list-style-type: none">Obtained in accordance with regulations, GCP, and protocol.Dated prior to participation of each subject in trial.Provided for direct access to records.Non-English speaking subjects must be consented in a language they can understand.<ul style="list-style-type: none">Save all written translations.Oral summary of approved English consent form must be documented and should be witnessed.Consents obtained for screening purposes must be retained even if the subject was not enrolled in the protocol.To document revisions of these trial-related documents that take effect during trial, save all versions submitted and approved by site's IRB/IEC:<ul style="list-style-type: none">Informed consent form.Any other written information provided to subjects.Continual reviews are at the directive of the site's IRB/IEC.Changes in consent forms due to protocol amendments and important safety information are at the directive of the site's IRB/IEC and/or sponsor.	<ul style="list-style-type: none">Central fileProtocol fileSubject's research record	<ul style="list-style-type: none">45CFR4621CFR5021CFR5621CFR312FDA Guidance: E6 GCP, Sections 1.28, 4.8, 8.3.12, 8.2.3, 8.3.2OHRP Informed Consent Guidance Information
Investigator's Brochures (IBs)	<ol style="list-style-type: none">To document that relevant and current scientific information about the investigational drug/agent has been provided to the investigator.Include updates to document that investigator is informed in a timely manner of relevant information as it becomes available.Keep on file a copy for EACH of the study drugs/agents used within the protocol.Include the following:<ul style="list-style-type: none">Only the most recent version.<ul style="list-style-type: none">All obsolete versions must be removed.Obsolete IBs must be shredded since they may contain proprietary information.Shred upon removal from file, or, upon trial completion.Addendum to IBs (e.g., all IND safety reports related to the drug/agent).	<ul style="list-style-type: none">Central fileProtocol file	<ul style="list-style-type: none">21CFR312FDA Guidance: E6 GCP, Sections 1.36, 5.12, 7, 8.2.1, 8.3.1

Page 8 of 9

KCMC Clinical Trials Unit	STANDARD OPERATING PROCEDURE	Effective Date	SOP-Number CTU 003-02
		Page 9 of 13	09 OCT 2006
Title: ESSENTIAL DOCUMENTS			
SOP References:		Supersedes: N/A	
IRB/IEC Approvals	<ol style="list-style-type: none">1. Copies of all materials submitted to the IRB/IEC, including any local committees as required by the IRB/IEC, for example but not limited to:<ul style="list-style-type: none">• Clinical Research Center Committee• Radiation Safety Committee• Maternal Fetal Committee• Other Hospital Committees per local site IRB/IEC requirements2. Dated proof of submission and IRB/IEC approval for the following for both initial submissions and submissions of revisions (if any). Revised documents must be labeled (e.g., date and/or version number) to differentiate them from previous versions.<ul style="list-style-type: none">• Advertisements – to document that recruitment measures are appropriate and not coercive.• Continuing/interim review of trial in accordance with regulations and local institution/IRB/IEC policy.• IND Safety Reports, Safety Memos, and Safety Alerts• Informed consent form• Investigator's Brochures• Protocol• Protocol Amendments and/or Letters of Amendment• Protocol-specific education materials• Subject compensation• Any other documents receiving IRB/IEC approval or their favorable opinion.• Any other written information to be provided to subjects, to document that subjects will be given appropriate written information (content and wording) to support their ability to give fully informed consent.• Any other pertinent communications with IRB/IEC or documentation required by the IRB/IEC.• Clarification memos <i>if required by local IRB/IEC</i>.3. Proof of IRB/IEC receipt is necessary only if required by the local IRB/IEC.	<ul style="list-style-type: none">• Central file• Protocol file	<ul style="list-style-type: none">• 45CFR46• 21CFR50• 21CFR56• 21CFR312• FDA Guidance: E6 GCP, Sections 3, 4.4, 4.5, 4.10, 5.11, 5.17.3, 8.2.3, 8.2.7, 8.3.2, 8.3.3, 8.3.19• OHRP IRB Guidebook
	Laboratory	<ol style="list-style-type: none">1. To document competence of local, central, or Group laboratories to perform protocol required tests and support reliability of results of medical/laboratory/standardized procedures/tests, one of the following must be on file:<ul style="list-style-type: none">• Certification of Compliance• Certification of Accreditation AND the agency certificate• Results of established quality control and/or external quality• Other validation2. To document current competency, updated files when:<ul style="list-style-type: none">• Existing certification/accreditation/validation expires.• A new laboratory is added or replaces an existing laboratory.	<ul style="list-style-type: none">• Central file• Group-supported central laboratories documents may be filed on Group web sites.• Normal values/reference ranges may be filed

Page 9 of 9

KCMC Clinical Trials Unit		STANDARD OPERATING PROCEDURE	Effective Date	SOP-Number CTU 003-02
			Page 10 of 13	09 OCT 2006
Title: ESSENTIAL DOCUMENTS				
SOP References:			Supersedes: N/A	
	3. Document normal values/ranges for medical/laboratory/standardized procedures/tests included in the protocol. <ul style="list-style-type: none"> Update when they are revised during the trial. Does not apply to tests that do not have established normal values/ranges. 4. The preceding (1-3) do NOT apply to laboratories that test protocol specimens but do NOT report any subject-specific results for the diagnosis, treatment or assessment of the health of subjects.	in subject records (e.g., on lab report)		
Monitoring Log	Dated signature of monitor for each study visit.	<ul style="list-style-type: none"> Central file 	<ul style="list-style-type: none"> 21CFR312 FDA Guidance: Monitoring FDA Guidance: E6 GCP, Section 5.18 	
Monitoring Reports	Copies of all site visit reports (hard copy or electronic) to document both the site visits and findings of the monitor.	<ul style="list-style-type: none"> Central file 	<ul style="list-style-type: none"> 21CFR312 FDA Guidance: E6 GCP, Sections 1.39, 5.18, 8.3.10 	
Pharmacy Accountability Records	Accountability records must be kept for all study drugs/agents provided as part of the protocol.	<ul style="list-style-type: none"> Pharmacy file 	<ul style="list-style-type: none"> 21CFR312 FDA Guidance: E6 GCP, Sections 4.6, 5.13, 5.14, 8.2.15, 8.3.8, 8.3.23, 8.4.1 	
Protocol	To document investigator and sponsor agreement to the protocol, amendments and CRFs; and, to document revisions of trial-related documents that take effect during trial: <ul style="list-style-type: none"> Initial version that the site received registration approval for Amendments and Letters of Amendment Subsequent versions Clarification memos Case report forms 	<ul style="list-style-type: none"> Protocol file 	<ul style="list-style-type: none"> 21CFR312 FDA Guidance: E6 GCP, Sections 1.44, 1.45, 4.5, 5.23, 6, 8.2.2, 8.3.2 	
Protocol Training	Documentation that trial procedures were reviewed with the investigator and investigator's trial staff: <ul style="list-style-type: none"> Summary of start-up calls Training meetings 	<ul style="list-style-type: none"> Protocol file 	<ul style="list-style-type: none"> 21CFR312 FDA Guidance: E6 GCP, Sections 4.5, 5.23, 8.2.20 	
Record of Retained Body	If any blood specimens, other body fluids and/or tissue	<ul style="list-style-type: none"> Central file 	<ul style="list-style-type: none"> FDA Guidance: 	

KCMC Clinical Trials Unit	STANDARD OPERATING PROCEDURE	Effective Date	SOP-Number CTU 003-02
		Page 11 of 13	09 OCT 2006
Title: ESSENTIAL DOCUMENTS			
SOP References:		Supersedes: N/A	
Fluids and/or Tissue Samples	samples are retained for long-term storage at the site/institution, document location and identification of the retained samples. (e.g., A laboratory data management or tracking system.)	<ul style="list-style-type: none">• Protocol file• Laboratory file	E6 GCP, Section 8.3.25 OHRP Guidance: Issues to Consider in the Research Use of Stored Data or Tissues
Screening and Enrollment / Randomization Logs	<ol style="list-style-type: none">1. To document identification of subjects who entered pretrial screening.2. To document chronological enrollment of subjects by trial number3. Screening and enrollment/randomization logs may be separate or combined.4. Include the following information:<ul style="list-style-type: none">• Initials of all patients screened for each study• Patient identification (PID), if patient receives one• Date screened• Date randomized<ul style="list-style-type: none">➢ If not randomized, indicate reason	<ul style="list-style-type: none">• Central file• Protocol file	<ul style="list-style-type: none">• 21CFR312• FDA Guidance: E6 GCP, Sections 8.3.20, 8.3.22
Subject Identification Code List	<ol style="list-style-type: none">1. To document that the investigator keeps a confidential list of names of all subjects allocated to trial numbers upon enrolling in the trial.2. Allows investigator/institution to permit identification of all subjects enrolled in the trial in case follow-up is required.3. List needs to be kept in a confidential manner.	<ul style="list-style-type: none">• Central file• Protocol file	<ul style="list-style-type: none">• FDA Guidance: E6 GCP, Sections 1.58, 8.3.21, 8.4.3
Serious Adverse Events (SAE) and Safety Reports	<ol style="list-style-type: none">1. Notification by originating investigator to sponsor of serious adverse events, related reports, and other safety information.2. Notification by sponsor to investigators of safety information.3. Where applicable, notification by sponsor or investigator to regulatory authorities and IRB/IEC:<ul style="list-style-type: none">• Unexpected serious adverse drug reactions• Other safety information	<ul style="list-style-type: none">• Central file• Protocol file	<ul style="list-style-type: none">• 45CFR46• 21CFR50• 21CFR56• 21CFR312• FDA Guidance: E6 GCP, Sections 1.1, 1.2, 1.50, 1.60, 4.11, 5.16, 5.17, 8.3.16, 8.3.17, 8.3.18
Signature Key/Log	<ol style="list-style-type: none">1. To document the signatures of individuals using initials in place of a full signature to sign CRFs and source documents.2. To document the signatures and initials of all persons authorized to make entries and/or corrections on CRFs. Include all site staff working on a study, such as:<ul style="list-style-type: none">• Clinicians• Physicians• Pharmacists	<ul style="list-style-type: none">• Central file• Protocol file	<ul style="list-style-type: none">• FDA Guidance: E6 GCP, Section 8.3.24

Page 11 of 9

KCMC Clinical Trials Unit	STANDARD OPERATING PROCEDURE	Effective Date	SOP-Number CTU 003-02
		Page 12 of 13	09 OCT 2006
Title: ESSENTIAL DOCUMENTS			
SOP References:		Supersedes: N/A	

	<ul style="list-style-type: none"> Data personnel Any other individuals authorized to make entries and/or corrections on CRFs. 3. Key/log must include: <ul style="list-style-type: none"> Initials Printed Signature Legal Signature, including first and last name Credentials (if appropriate) 		
Signed Agreements	To document agreements between involved parties, if any. For example: <ul style="list-style-type: none"> Investigator/institution and sponsor (e.g., grant) Investigator/institution and affiliated sites (e.g., contracts) Investigator/institution and authorities (where required) 	<ul style="list-style-type: none"> Central file Business office file 	<ul style="list-style-type: none"> 21CFR312 FDA Guidance: E6 GCP, Sections 4.9.6, 5.6, 8.2.6
Source Documents	1. To document the existence of the subject and substantiate integrity of trial data collected. 2. To include original documents related to the trial, medical treatment, and history of subject. 3. Electronic media, original documents or certified copies. 4. Refer to the KCMC Clinical Research Source Documentation SOP for additional requirements.	<ul style="list-style-type: none"> As per requirements of local institution. 	<ul style="list-style-type: none"> 21CFR11 21CFR312 FDA Guidance: E6 GCP, Sections 1.51, 1.52, 5.20, 8.3.13
Unblinding	A copy of the group's/protocols SOP for unblinding must be on file at the site.	<ul style="list-style-type: none"> Central file Protocol file 	<ul style="list-style-type: none"> 21CFR312 FDA Guidance: E6 GCP, Sections 1.10, 4.7, 8.2.17, 8.4.6

This SOP has been read and understood by:

Name	Date
1.	
2.	
3.	
4.	

